Evidence map›Paper›PMID 25885813›Full record

ArticleBMC cancer2015

Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.

Bruna C Guido, Luciana M Ramos, Diego O Nolasco, Catharine C Nobrega, Bárbara Y G Andrade, Aline Pic-Taylor, Brenno A D Neto, José R Corrêa

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Kinesin Spindle Protein (KIF11) in Mitosis and Cancer.International journal of molecular sciences · 2025
    Review
  3. Targeting Breast Cancer: Novel Dihydropyrimidinones As Potent Eg5 Inhibitors.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Article
  4. Article
  5. Role of motor proteins in human cancers.Saudi journal of biological sciences · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Monastrol derivatives:Research in pharmaceutical sciences · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Bruna C GuidoDepartment of Cell Biology, Laboratory of Electron Microscopy, University of Brasília (IB-UnB), Campus Universitário Darcy Ribeiro, Brasília, DF, Brazil. brunacguido@gmail.com.
Luciana M RamosLaboratory of Medicinal and Technological Chemistry, University of Brasília (IQ-UnB), Brasília, Distrito Federal, Brazil. lucianamramos@hotmail.com.
Diego O NolascoResearch Laboratory of Electronics, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA. nolasco@mit.edu.
Catharine C NobregaDepartment of Cell Biology, Laboratory of Electron Microscopy, University of Brasília (IB-UnB), Campus Universitário Darcy Ribeiro, Brasília, DF, Brazil. catharine_carrara@hotmail.com.
Bárbara Y G AndradeDepartment of Cell Biology, Laboratory of Electron Microscopy, University of Brasília (IB-UnB), Campus Universitário Darcy Ribeiro, Brasília, DF, Brazil. barbarayasmi@gmail.com.
Aline Pic-TaylorLaboratory of Embryology and Developmental Biology, Genetics and Morphology Department, University of Brasília (IB-UnB), Brasília, Distrito Federal, Brazil. alinepic@unb.br.
Brenno A D NetoLaboratory of Medicinal and Technological Chemistry, University of Brasília (IQ-UnB), Brasília, Distrito Federal, Brazil. brenno.ipi@gmail.com.
José R CorrêaDepartment of Cell Biology, Laboratory of Electron Microscopy, University of Brasília (IB-UnB), Campus Universitário Darcy Ribeiro, Brasília, DF, Brazil. correa@unb.br.
Universidade de Brasília · BRUniversidade Católica de Brasília · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is a complex heterogeneous disease and is one of the leading causes of death among women. In addressing the need for treatments of this life-threatening illness, we studied 3,4-dihydropyrimidin-2(1H)-one (or thione) derivatives (DHPMs), a class of inhibitor molecules of the Eg5 motor spindle protein that shows pronounced antitumor activity against several cancer cell lines.

methodsAn in vitro screening was performed for identification of DHPMs with potent antitumor effects on MCF-7 and MDA-MB-231 cells and the selected DHPMs were evaluated for their inhibitory activity on Eg5 both in silico, using Molecular dynamics, and in vitro Eg5 inhibition assays. Analysis of cell death induction, proliferation, cell cycle and cancer stem cells (CSC) profile were performed by flow cytometry to assess the influence of the selected DPHMs on these important tumor features. Finally, the effects of DHPM treatment on tube formation were evaluated in vitro using HUVEC cells, and in vivo using a model on chorioallantoic membrane (CAM) of fertilized eggs.

resultsWe identified five DHPMs with pronounced inhibitory activity on Eg5 motor protein interfering with the proper mitotic spindle assembly during cell division. These compounds impair the correct conclusion of cell cycle of the breast cancer cells and showed to be selective for tumor cells. Moreover, DHPMs modulate the CD44(+)/CD24(-) phenotype leading to a decrease in the CSC population in MDA-MB-231 cells, an important effect since CSC are resistant to many conventional cancer therapies and play a pivotal role in tumor initiation and maintenance. This observation was confirmed by the results which demonstrated that DHPM treated cells had impaired proliferation and were unable to sustain angiogenesis events. Finally, the DHMP treated cells were induced to apoptosis, which is one of the most pursued goals in drug development.

conclusionsThe results of our study strongly suggest that DHPMs inhibit important tumorigenic features of breast cancer cells leading them to death by apoptosis. These findings firmly point to DHPM molecular architecture as a promising alternative against breast cancer.

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCell CycleCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugEnzyme ActivationFemaleHumansInhibitory Concentration 50KinesinsModels, MolecularMolecular ConformationNeoplastic Stem CellsAntineoplastic AgentsKIF11 protein, humanKinesinsPyrimidines

Identifiers

PMID25885813
PMCPMC4411898
OpenAlexW2031041310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.